NKTX News - Candlesense

Nkarta to Participate in a September Investor Conference

(NASDAQ:NKTX) SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cel...

Investor

5 days ago

Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, to...

Is there any indication of upcoming milestones that could trigger a catalyst-driven price movement? What are the potential risks related to trial enrollment rates and endpoint achievement for the autoimmune programs? How might the Q2 earnings results influence analyst coverage and consensus estimates for NKTX?

Earnings

25 days ago